CGEM
Cullinan Therapeutics, Inc.·Healthcare
14.54
4.405%(−0.67)
Market ClosedLast Updated: — ET
52W L: $5.6852W H: $16.74
CGEM NEWS
defenseworld.net
Mar 28
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations. Analyst Recommendations This is a breakdown of recent
defenseworld.net
Mar 14
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners' Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially "defining year" driven by multiple clinical readouts across its pipeline. Chief Executive Officer Nadim and Chief Medical Officer Jeff highlighted two "high-priority" T-cell engager (TCE) programs-CLN-978 in autoimmune diseases and
globenewswire.com
Mar 10
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2025.
defenseworld.net
Mar 9
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the company's two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthcare Conference, pointing to multiple data readouts in autoimmune disease in 2026 and an expansion plan for its acute myeloid leukemia (AML) program. Management frames 2026 as a catalyst year President
defenseworld.net
Feb 25
Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $223,109.22. Following the transaction, the chief executive officer directly owned 404,318 shares in
defenseworld.net
Feb 25
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $14.08, for a total transaction of $165,327.36. Following the completion of the sale, the insider directly owned 181,977 shares of the
